No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:56:09.210Z. Latest historical point 2022-05-16. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:56:09.210Z. Latest historical point 2023-08-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:56:09.210Z. Latest historical point 2023-08-10.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:56:09.210Z. Latest historical point 2023-08-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cullinan Therapeutics, Inc. (CGEM) stock was $16.04 as of Oct 5, 2026, 4:00 PM EDT, up 3.42% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +170.6% · 3-year avg +22.9%/yr · 5-year avg -7.5%/yr
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.84
Revenue Est.
$2.00M
Last Quarter Results
EPS
$-0.81
vs Estimate
$-0.85
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CGEM | $985.79M | $16.04 | +3.42% | +170.57% | -7.48% | N/A | N/A |
| 2AKTS | $989.05M | $18.52 | +0.00% | N/A | N/A | N/A | vs CGEM |
| 3CBLL | $943.26M | $24.86 | +4.94% | +96.04% | N/A | N/A | vs CGEM |
| 4ABUS | $922.50M | $4.67 | +4.94% | +6.59% | +2.19% | +2.93% | vs CGEM |
| 5TDOC | $1.05B | $5.79 | +4.89% | -35.60% | -45.85% | -10.53% | vs CGEM |
| 6BVS | $915.95M | $13.52 | +2.97% | +91.99% | -0.81% | N/A | vs CGEM |
forward FY estimate
N/A
$0.00
vs Estimate
$3.67M
Consensus Rating
Based on 11 analysts
Average Price Target
$33.45
+108.6% upside
Low
$23.00
Current
$16.04
High
$42.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.96 | $-0.84 | $-0.76 | 7 |
| Quarter ending Dec 2026 | $-0.92 | $-0.71 | $-0.36 | 7 |
| Quarter ending Mar 2027 | $-0.57 | $-0.57 | $-0.57 | 2 |
| Quarter ending Jun 2027 | $-0.84 | $-0.84 | $-0.84 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.64 | $-3.17 | $-2.79 | 8 |
| FY 2027 | $-3.50 | $-2.50 | $-1.57 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.00M | $2.00M | $2.00M | 1 |
| Quarter ending Dec 2026 | $13.00M | $13.00M | $13.00M | 5 |
| Quarter ending Mar 2027 | $15.25M | $15.25M | $15.25M | 4 |
| Quarter ending Jun 2027 | $2.07M | $2.07M | $2.07M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $8.85M | $12.62M | $19.08M | 7 |
| FY 2027 | $20.09M | $57.84M | $122.57M | 8 |
